Bioengineering Research Grants (BRG) (R01 Clinical Trial Optional)
ID: 360543Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/360543
Timeline
    Description

    The National Institutes of Health (NIH) is offering Bioengineering Research Grants (BRG) under the R01 Clinical Trial Optional program, aimed at fostering collaborations between life and physical sciences to address biomedical challenges. The grants encourage multidisciplinary bioengineering approaches that integrate and accelerate the adoption of innovative tools and methods for research or clinical problems in basic, translational, or clinical science. This funding opportunity is particularly significant for small teams looking to enhance understanding and solve issues in biological and clinical sciences. Interested applicants can reach out to Dr. Miguel R. Ossandon at ossandom@mail.nih.gov or by phone at 240-276-5714, with an estimated award date of December 1, 2026, and a closing date for applications on February 5, 2026. The program anticipates awarding approximately 50 grants, with no cost-sharing or matching requirements.

    Point(s) of Contact
    Miguel R. Ossandon, Ph.D.
    (240) 276-5714
    Email: ossandom@mail.nih.gov
    Files
    No associated files provided.
    Similar Opportunities
    Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering funding through the Exploratory/Developmental Bioengineering Research Grants (EBRG) program, aimed at enhancing biomedical research and clinical care. This initiative encourages innovative applications that focus on developing new capabilities to address challenges in biomedical, preclinical, or clinical settings, with an emphasis on feasibility testing and novel methodologies. The program is particularly significant for advancing cancer research through innovative bioengineering approaches, welcoming proposals from a diverse range of eligible applicants, including universities, nonprofits, and small businesses, especially those representing underrepresented groups. The maximum budget for applicants is $275,000 over two years, with applications due by January 7, 2028. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-25-321.html.
    Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Not Allowed), aimed at advancing innovative bioengineering solutions to address cancer and other biomedical challenges. This funding opportunity encourages projects that demonstrate the feasibility and potential utility of novel capabilities to enhance biomedical research, clinical care delivery, and accessibility, while specifically discouraging clinical trial proposals. Eligible applicants include a diverse range of institutions such as higher education entities, nonprofits, for-profit organizations, and foreign entities, with a funding cap of $275,000 available over a two-year period. Interested applicants can find more information and submission guidelines on the NIH website, with applications due by January 7, 2028. For inquiries, contact NIH Grants Information at grantsinfo@nih.gov.
    Bioengineering Partnerships with Industry (U01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Bioengineering Partnerships with Industry (U01 Clinical Trial Optional)" aimed at fostering collaborative research partnerships between academic and industrial investigators to accelerate the development of innovative bioengineering tools and technologies. The program seeks to establish multidisciplinary teams that apply a quantitative bioengineering approach to address significant biomedical challenges, with a focus on creating robust solutions that can enhance life science understanding and medical practices within a 5-10 year timeframe. Eligible applicants include a diverse range of organizations such as higher education institutions, nonprofits, and for-profit entities, particularly those emphasizing diversity in research. Interested parties should note that the application deadline is September 7, 2027, and for further inquiries, they can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information page at https://grants.nih.gov/grants/guide/pa-files/PAR-24-325.html.
    Bioengineering Research, Innovation and Technology Education (BRITE) Program (R25 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Bioengineering Research, Innovation and Technology Education (BRITE) Program, a federal grant aimed at fostering the development of undergraduate students in bioengineering and related STEM fields. This program encourages private institutions of higher education to propose integrated educational activities that include a summer bridge program for incoming freshmen, academic year activities, and summer research experiences, ultimately guiding participants toward doctoral degrees or research careers in bioengineering and biomedical imaging. The BRITE Program is crucial for enhancing the capacity for rigorous bioengineering training and addressing the nation's health-related research needs. Interested applicants can contact Dr. Tina Gatlin at gatlincl@nih.gov or by phone at 240-731-3794, with the estimated project start date set for March 1, 2027, and the application window closing on May 11, 2026.
    Collaborative Program Grant for Multidisciplinary Teams (RM1 - Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Collaborative Program Grant for Multidisciplinary Teams (RM1), aimed at funding integrated research teams of three to six Program Directors/Principal Investigators (PDs/PIs) to tackle complex biomedical questions. This initiative emphasizes the need for collaborative efforts that demonstrate synergy and diversity, with the goal of achieving significant scientific advancements within the mission of the National Institute of General Medical Sciences (NIGMS). Funding is available for new, renewal, and resubmission applications, with anticipated budgets ranging from $700,000 to $1.5 million per year, and applications must be submitted by January 27, 2026. Interested applicants can find more information and guidelines at the NIH Grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    NIH Research Project Grant (Parent R01 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the NIH Research Project Grant, designated as the Parent R01 Clinical Trial Required (Funding Opportunity Number PA-25-305). This grant supports discrete research projects that include at least one clinical trial and align with the scientific missions of participating NIH Institutes and Centers. The initiative aims to foster innovative health-related research and enhance scientific resources, with applications accepted from a diverse range of organizations, including higher education institutions and community-based organizations. Applications will open on January 5, 2025, with subsequent submission deadlines throughout 2025 and 2026, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Notice of Intent to Publish a Funding Opportunity Announcement for Trailblazer Award for New and Early-Stage Investigators (R21 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) plans to publish a Notice of Funding Opportunity (NOFO) for the Trailblazer Award aimed at New and Early-Stage Investigators, with a focus on integrating engineering and physical sciences with life and biomedical sciences. This grant opportunity, utilizing the R21 activity code, encourages innovative research projects that may be exploratory, developmental, or high-risk high-impact, and aims to foster collaborations that open new areas of biomedical investigation. Interested applicants, particularly those with expertise in engineering and quantitative sciences, should prepare to submit their applications once the NOFO is officially released, with an estimated synopsis post date of November 21, 2025, and a projected award date of October 1, 2026. For further inquiries, potential applicants can contact Randy King at the National Institute of Biomedical Imaging and Bioengineering via email at Randy.King@nih.gov or by phone at 301-451-0707.
    Trailblazer Award for New and Early Stage Investigators (R21 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Trailblazer Award for New and Early Stage Investigators, a federal grant aimed at fostering innovative biomedical research that integrates engineering with life sciences. This funding opportunity, under the R21 Exploratory/Developmental Research Grant mechanism, allows for up to $400,000 in direct costs over a three-year period for projects that require minimal preliminary data, encouraging high-risk, high-reward research. The initiative is designed to enhance diversity within the research community and is open to a wide range of eligible applicants, including various educational institutions and community organizations. Interested parties should note that the application submission period opens on January 16, 2025, and closes on January 8, 2026; for further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    NIH Director’s Transformative Research Awards (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is set to announce the NIH Director’s Transformative Research Awards, a federal grant opportunity aimed at supporting innovative and unconventional research projects. This program encourages individual scientists or collaborative teams to propose groundbreaking research that has the potential to redefine scientific paradigms or develop transformative technologies, without the need for preliminary data or detailed experimental plans. With an estimated total funding of $8 million and the expectation of awarding seven grants, interested applicants should prepare their proposals in advance, as applications will be solicited starting June 20, 2025, with a closing date of September 3, 2025. For further inquiries, potential applicants can contact Dr. Patricia Labosky at TransformativeAwards@mail.nih.gov or by phone at 301-594-4863.
    Focused Technology Research and Development (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) for the Focused Technology Research and Development (R01 Clinical Trial Not Allowed) grant, aimed at supporting innovative technology projects that advance biomedical research. Eligible applicants include a diverse range of institutions, such as Historically Black Colleges and Universities, Tribal Colleges, and various community-based organizations, with a focus on projects that demonstrate proof-of-concept and the development of working prototypes without integrating clinical trials. This initiative is crucial for fostering technological advancements that enhance understanding of biological processes, with no budget cap and a maximum project duration of five years. Interested applicants can find more information and application guidelines at NIH Grants, with proposals due by January 7, 2028.